Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, posted on X:
“SABCS24 day 1 kicks off with an interesting FDA Oncology special session on drug approval. First talk tackles the approval of adjuvant ribociclib per NATALEE. Two post-marketing commitments: to provide efficacy in a broader diverse population, and to provide updates on OS.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.